This section of ASIA by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Indian Institute Joins Waters
Innovation Program Waters has announced the selection of St. John’s Research Institute (Bangalore) as the first Institution in India for its Centres of Innovation Program for research in the field of structural proteomics. Under the direction of Professor Dr Amit Kumar Mandal, a Professor of Molecular Medicine and Clinical Proteomics, St. John’s has earned a reputation for its research in blood disorders and other diseases that disproportionately affect disadvantaged populations.
“What you see today is a culmination of a great amount of dedication and passion on the part of Professor Mandal. Our relationship with Waters is not just one of a client and vendor; it is a true working partnership and has been ever since this laboratory came into existence in 2009,” said K. Srinivasan, Dean, St. John’s Research Institute in remarks during the ceremony.
On hand to congratulate Professor Mandal and his team was K.V. Venugopalan, President, Waters India Pvt. Ltd. “We are proud to be associated with Professor Mandal’s outstanding and pioneering work in structural proteomics,” he said. “Partnering with St. John’s Research Institute is a reflection of our mutual interests in serving society by improving the health of patient communities through science.”
Professor Mandal and his research colleagues are using a combination of Waters’ UPLC and mass spec systems with an electrospray ionization source, a MALDI source, and an option for doing hydrogen deuterium exchange mass spectrometry to gain (HDXMS)new insights into the structural changes associated with post-translational modifications of hemoglobin variants.
More Info. 162
IDS Moves into Chinese Diagnostics Market
Immunodiagnostic Systems (IDS) a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, has appointed Beijing Leadman Biochemistry Technology Co as its exclusive distributor for the IDS-iSYS instrument and assays in the People’s Republic of China. The two partners have also agreed on the planned conversion of over 50 of Leadman’s proprietary immunoassays for use on the IDS- iSYS instrument.
Established in 1997 Leadman, a leading developer, manufacturer and distributor of in vitro diagnostic products in China, is headquartered in the Beijing Economic-
Technological Development Area where it operates its R&D centre and reference laboratory. Leadman’s sales network covers 28 provinces in China, with 8 regional sales offices and over 2,000 customers.
The 3 year distribution agreement will commence from the date of the China Food and Drug Administration (CFDA) approval of the IDS- iSYS instrument and the first IDS assay anticipated to take around 12-14 months.
Under the agreement terms over 300 IDS-iSYS instruments could be placed by Leadman and its sub-distributors in the Chinese market during the 3 year period, reported IDS.
Vectura Enters Respiratory Business in China More Info. 160
Vectura Group plc has established Tianjin Kinnovata Pharmaceutical Company Ltd in China with two partners; Tianjin KingYork Group, a leading Chinese manufacturer of corticosteroid based products and Hong Kong-based private equity investor Zendex Bio Strategy Inc.
Kinnovata will develop, manufacture and commercialise respiratory products for the domestic Chinese and other regional markets in Asia, initially using Vectura’s Clickhaler® Duohaler®
and
dry powder inhaler (DPI) technology platforms. Patient population estimates suggested a 2% overall incidence of asthma in China, affecting more than 25 million people;
with COPD affecting approximately 42 million, rising to around 56 million people by 2021.
Kinnovata’s manufacturing facility will be based on KingYork’s pharmaceutical business park in Tianjin. Mr Chris Chan, previously an advisor to Zendex, has been appointed CEO of the Company.
“There is a strong appetite in China for Western branded products and Kinnovata aims to introduce high quality affordable products made locally in China using Western technology,” Mr Chan said.
Completion of the transaction is subject to final Government clearances in China.
More Info. 161 BioTek Continues Push into Asia Markets
BioTek Instruments, Inc. continues its expansion in the Asia Pacific region with the opening of a new office in Taiwan located in the Neihu District of Taipei. Mr Jack Lu (Lu Wen-Chung), previously with Tseng Hsiang Life Science, was named General Manager of BioTek Taiwan at its inception in mid-April. The new office will focus on supporting current and potential customers increasing BioTek's brand presence in Taiwan.
More Info. 163
"Taiwan's biotechnology and scientific sectors are expanding; supported by the government's focus and investment," noted Dominic Herring, BioTek's Business Development Manager. "Our direct office in Taiwan will allow us to provide local, strong and immediate applications and service support to our expanding customer base, in a market that continues to demonstrate high quality scientific research."
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220 |
Page 221 |
Page 222
